Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New medicinal application of effective components and derivatives thereof in Glycyrrhiza uralensis

A technology of active ingredients and derivatives, applied in the field of medicine, can solve problems such as large side effects and damage to human cell activity

Inactive Publication Date: 2020-02-21
JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no information about the active ingredients in licorice, such as glycyrrhizin, liquiritigenin, glycyrrhetinic acid, isoliquiritigenin, licorice chalcone A, glycyrrhizic acid ( glycyrrhizic acid) and its derivatives monoammonium glycyrrhizinate (Monoammonium glycyrrhizinate, MAG) combined with one or more pharmaceutically acceptable carriers or excipients to make the active ingredients in licorice and its derivatives pharmaceutical composition or Reports or patents on preparations used to induce immunogenic death of tumor cells
[0005] Most of the existing anticancer drugs use antibiotics and other stimulant drugs to inhibit tumors, which will destroy the activity of human cells after long-term use, and have great side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New medicinal application of effective components and derivatives thereof in Glycyrrhiza uralensis
  • New medicinal application of effective components and derivatives thereof in Glycyrrhiza uralensis
  • New medicinal application of effective components and derivatives thereof in Glycyrrhiza uralensis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Mouse colon cancer cells were cultured in the drug environment, and cell proliferation was detected by CCK-8. The reagent contains WST-8 [chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonic acid benzene )-2H-tetrazolium monosodium salt], which is reduced by the dehydrogenase in the cell to have Highly water-soluble yellow formazan product. The amount of formazan produced is directly proportional to the number of living cells. This feature can therefore be used directly for cell proliferation and toxicity assays. Specific steps are as follows:

[0030] Step 1: Inoculate CT-26 cell suspension (mouse colon cancer cells) in a 96-well culture plate and culture for 1 day until the density of the cell monolayer is 60%;

[0031] Step 2: Incubate with DMEM culture solution for 15 minutes, add a series of DMSO solutions of different concentrations of liquiritin, glycyrrhizin, glycyrrhetinic acid, isoliquiritigenin, licochalcone A, glycyrrhizic acid ...

Embodiment 2

[0035] Mouse colon cancer cells were cultured in the drug environment, and the transfer of CRT from the endoplasmic reticulum to the cell membrane surface was detected by immunofluorescence. CRT is a calcium-binding protein present in the endoplasmic reticulum, involved in folding during protein synthesis, and by binding Ca 2+ Increases Ca in the endoplasmic reticulum 2+ stability. During apoptosis, CRT is exposed to the tumor microenvironment, recruits and stimulates the maturation of antigen-presenting cells with the "eat me" signal, binds to surface receptors, and stimulates Rac-1 to promote the phagocytosis of tumor cells. The everted extramembrane expression of CRT is critical for triggering T cell-dependent antitumor immunity. Specific steps are as follows:

[0036] Step 1: Inoculate CT-26 cell suspension (mouse colon cancer cells) in a 6-well culture plate and culture for 1 day until the density of the cell monolayer is 60%;

[0037] Step 2: Incubate with DMEM cultu...

Embodiment 3

[0042] Mouse colon cancer cells were cultured in drug environment, and ELISA was used to detect the release of HMGB1. HMGB1 is widely distributed and is a cytokine related to inflammatory response, which is highly expressed in the nucleus and regulates chromatin structure and gene transcription. At homeostasis, HMGB1 shuttles between the cytoplasm and nucleus. In the late stage of ICD, due to the damaged nucleus and plasma membrane, HMGB1 is exposed on the surface of apoptotic cells, binds to many receptors on antigen presenting cells (APC), and activates the inflammatory pathway response. Specific steps are as follows:

[0043] Step 1: Inoculate CT-26 cell suspension (mouse colon cancer cells) in a 6-well culture plate and culture for 1 day until the density of the cell monolayer is 60%;

[0044] Step 2: Incubate with DMEM culture medium for 15 minutes, add liquiritin, glycyrrhizin, glycyrrhetinic acid, isoliquiritigenin, licochalcone A, glycyrrhizic acid and DMSO solution ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new medicinal application of effective components and derivatives in Glycyrrhiza uralensis. The effective components and derivatives in Glycyrrhiza uralensis include liquiritin, glycyrrhizin, glycyrrhetinic acid, isoliquiritigenin, licochalcone A, glycyrrhizic acid and its derivative glycyrrhizic acid monoammonium salt, and the effective components and derivatives in Glycyrrhiza uralensis are used for preparing anticancer drugs. As that effective component in Glycyrrhiza uralensis and its derivative can induce tumor cells to produce immunogenic cell death. The invention provides a tumor treatment drug with definite curative effect, safety, convenience and wide sources, which can be combined with one or more pharmaceutically acceptable carriers or excipients to prepare pharmaceutical compositions or preparations of active components in licorice and derivatives thereof, it provides new drugs for tumor immunotherapy and is of great significance for improving tumor therapeutic effect and quality of life of patients. The effective components come from fruits, vegetables and medicinal materials, with small side effects, low cost and convenient popularization anduse.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a new medical application of active ingredients in licorice and derivatives thereof. Background technique [0002] While physical and chemical factors induce tumor cell apoptosis, tumor cells change from non-immunogenic to immunogenic, and thus activate specific T lymphocytes, induce the body to produce specific cellular immune responses, and achieve the purpose of eradicating tumors , which is immunogenic cell death (immunogenic cell death, ICD). Once tumor immunogenic cell death (ICD) is induced, the ratio of cytotoxic T cells (cytotoxic Tlymphocyte, CTL) / Treg in the tumor increases, and the prognosis of patients is good. The importance of anti-tumor immunity. Immunotherapy such as PD-1 antibody and chimeric antigen receptor therapy (CART) are expected to become the fourth tumor treatment method. Immunotherapy was rated as a major scientific breakthrough in 2013 by Science. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/484A61K31/704A61K31/122A61K31/12A61K31/56A61K31/7048A61P35/00
CPCA61K31/12A61K31/122A61K31/56A61K31/704A61K31/7048A61K36/484A61P35/00
Inventor 张婧李翔
Owner JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com